TAZ

Across TCGA pan-cancer cohorts, TAZ mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TAZ data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TAZ mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TAZ expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, COAD, and LUAD are the cancer types where TAZ mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.289	0.781	.002	21	view →
COAD	DFS	Median	III,IV	0.785	1.000	.043	6	view →
LUAD	DFS	Median	All	0.872	0.949	.008	6	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.797	.024	5	view →
HNSC	DFS	Median	II,III,IV	0.880	0.545	.042	2	view →
CCRCC	DFS	Tertile	All	1.000	0.662	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TAZ–PDAC (OS)

Open the PDAC breakdown →